AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario
AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m.…
07 Sep 2026
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib), for breast cancer.…
04 Sep 2026
Pineapples and green tea: FDA turns to public for new approaches to botanical drugs
The US Food and Drug Administration (FDA) is requesting public input on both the opportunities and challenges regarding drugs derived from botanical sources. Botanical drug products are those developed from…
04 Sep 2026
Ionis nets Zanvastro US approval in first for Alexander disease
Ionis Pharmaceuticals has secured an approval from the US Food and Drug Administration (FDA) for its therapy, zilganersen, in the rare neurodegenerative disorder Alexander disease – marking the first time…
04 Sep 2026
FDA rallies HRT manufacturers amid US-wide estradiol patch shortage
The US Food and Drug Administration (FDA) has started working with six drug-device manufacturers involved in the production of transdermal estradiol patches to bolster supplies to the American public amid…
04 Sep 2026
Superluminal Medicines secures $60m to advance rare obesity therapy
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity. The funding…
04 Sep 2026
Médunik and Biocodex sign exclusive agreement for Diacomit in Canada
Médunik Canada has entered an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an add-on therapy for seizures associated with Dravet syndrome. The agreement…